Company Overview and News

 
St Barbara takes 12.3% stake in Duketon Mining

2018-04-05 australianmining.com.au
Australian gold exploration and production company St Barbara has paid $4 million for 14.5 million shares of Duketon Mining at a price of 27.5 cents per share, representing a 12.3 per cent investment in the company.
Upvote Downvote

 
Duketon Mining surges after St Barbara Ltd’s $4 million investment in gold-nickel strategy

2018-04-04 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has surged to a new 12-month high of 30 cents on news of a $4 million investment by mid-tier gold producer St Barbara Ltd (ASX:SBM).
Upvote Downvote

 
Navarre Minerals starts major drilling program in quest for Victorian gold

2018-02-12 proactiveinvestors.com.au
Navarre Minerals Limited (ASX:NML) has started a major drilling program targeting gold at five projects in central and western Victoria.
Upvote Downvote

 
St Barbara forecasts higher gold production

2018-01-09 australianmining.com.au
The miner, which operates the Gwalia operation in Western Australia and Simberi mine in Papua New Guinea, now expects to produce from 365,000 to 385,000 ounces (oz) of gold in 2017–2018, an increase from its previous guidance of 350,000 to 375,000oz.
Upvote Downvote

 
Miners in $12m of raisings

2017-07-31 businessnews.com.au
Three local resources companies have announced successful raisings worth a total of $12 million today, with uranium hopeful Vimy Resources, gold focused Explaurum and gold explorer Catalyst Metals all raising capital.
Upvote Downvote

 
Catalyst Metals hits high-grade gold at Tandarra Gold Project

2017-07-26 proactiveinvestors.com.au
Catalyst Metals (ASX:CYL) has intersected shallow high-grade gold at the Tomorrow Gold Zone, part of the Tandarra Gold Project in Victoria.
Upvote Downvote

 
Share placement

2016-04-07 asx.com.au
Upvote Downvote

 
Half year accounts

2016-03-14 asx.com.au
Upvote Downvote

 
Catalyst Metals Ltd in 100g/t gold hit

2016-03-09 proactiveinvestors.com.au
Catalyst Metals (ASX: CYL) holds interests in advanced gold and molybdenum projects located in Victoria and Western Australia.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...